168.81BMarket Cap
14.54P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Novo Nordisk A/S
Currency: USD Updated: 2025-12-12 Key Insights
Novo Nordisk A/S's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 58/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 56.41.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novo Nordisk A/S's Score
Score Analysis
Current score
Previous score
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Novo Nordisk A/S Highlights
StrengthsRisks
Financial Health
Currency: USD Updated: 2025-12-12 The current financial score of Novo Nordisk A/S is 8.91, ranking 29/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.74B, representing a year-over-year increase of 11.81%, while its net profit experienced a year-over-year increase of 22.07%.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Key Metrics
Relevant data have not been disclosed by the company yet.
Novo Nordisk A/S's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of Novo Nordisk A/S is 7.37, ranking 77/159 in the Pharmaceuticals industry. Its current P/E ratio is 14.54, which is 247.82% below the recent high of 50.57 and 14.20% above the recent low of 12.47.
Valuation Dimensions
Industry Ranking 58/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of Novo Nordisk A/S is 6.33, ranking 128/159 in the Pharmaceuticals industry. The average price target for Novo Nordisk A/S is 53.39, with a high of 90.39 and a low of 41.90.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Strong Buy
Buy
Hold
Sell
Strong Sell
Vertex Pharmaceuticals Inc
VRTX
33
Financial Forecasting
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of Novo Nordisk A/S is 9.01, ranking 46/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 52.93 and the support level at 45.26, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of Novo Nordisk A/S is 3.00, ranking 92/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 9.08%, representing a quarter-over-quarter decrease of 7.50%. The largest institutional shareholder is Ken Fisher, holding a total of 10.32M shares, representing 0.31% of shares outstanding, with 13.03% decrease in holdings.
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Capital International Investors
Loomis, Sayles & Company, L.P.
Fidelity Management & Research Company LLC
Managed Account Advisors LLC
Parametric Portfolio Associates LLC
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of Novo Nordisk A/S is 7.29, ranking 44/159 in the Pharmaceuticals industry. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Beta vs S&P 500 index
0.66
240-Day Maximum Drawdown
+50.56%
240-Day Volatility
+52.94%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Novo Nordisk A/S?
The TradingKey Stock Score provides a comprehensive assessment of Novo Nordisk A/S based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Novo Nordisk A/S’s performance and outlook.
How do we generate the financial health score of Novo Nordisk A/S?
To generate the financial health score of Novo Nordisk A/S, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Novo Nordisk A/S's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Novo Nordisk A/S.
How do we generate the company valuation score of Novo Nordisk A/S?
To generate the company valuation score of Novo Nordisk A/S, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Novo Nordisk A/S’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Novo Nordisk A/S’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Novo Nordisk A/S.
How do we generate the earnings forecast score of Novo Nordisk A/S?
To calculate the earnings forecast score of Novo Nordisk A/S, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Novo Nordisk A/S’s future.
How do we generate the price momentum score of Novo Nordisk A/S?
When generating the price momentum score for Novo Nordisk A/S, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Novo Nordisk A/S’s prices. A higher score indicates a more stable short-term price trend for Novo Nordisk A/S.
How do we generate the institutional confidence score of Novo Nordisk A/S?
To generate the institutional confidence score of Novo Nordisk A/S, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Novo Nordisk A/S’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Novo Nordisk A/S.
How do we generate the risk management score of Novo Nordisk A/S?
To assess the risk management score of Novo Nordisk A/S, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Novo Nordisk A/S’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Novo Nordisk A/S.
